Confirming the bidirectional nature of the association between severe hypoglycemic and cardiovascular events in type 2 diabetes: Insights from Exscel by Standl, E. et al.
Confirming the Bidirectional
Nature of the Association Between
Severe Hypoglycemic and
Cardiovascular Events in Type 2
Diabetes: Insights From EXSCEL
Diabetes Care 2020;43:643–652 | https://doi.org/10.2337/dc19-1079
OBJECTIVE
We sought to confirm a bidirectional association between severe hypoglycemic
events (SHEs) and cardiovascular (CV) event risk and to characterize individuals at
dual risk.
RESEARCH DESIGN AND METHODS
In a post hoc analysis of 14,752 Exenatide Study of Cardiovascular Event Lowering
(EXSCEL) participants, we examined time-dependent associations between SHEs
and subsequent major adverse cardiac events (CV death, nonfatal myocardial
infarction [MI] or stroke), fatal/nonfatal MI, fatal/nonfatal stroke, hospitalization
for acute coronary syndrome (hACS), hospitalization for heart failure (hHF), and all-
causemortality (ACM), aswell as time-dependentassociationsbetweennonfatal CV
events and subsequent SHEs.
RESULTS
SHEs were uncommon and not associated with once-weekly exenatide therapy
(hazard ratio1.13 [95%CI0.94–1.36],P50.179). In fully adjustedmodels, SHEswere
associated with an increased risk of subsequent ACM (1.83 [1.38–2.42], P < 0.001),
CV death (1.60 [1.11–2.30], P5 0.012), and hHF (2.09 [1.37–3.17], P5 0.001), while
nonfatal MI (2.02 [1.35–3.01], P 5 0.001), nonfatal stroke (2.30 [1.25–4.23], P 5
0.007), hACS (2.00 [1.39–2.90],P<0.001), andhHF (3.24 [1.98–5.30],P<0.001)were
all associated with a subsequent increased risk of SHEs. The elevated bidirectional
time-dependent hazards linking SHEs and a composite of all CV events were
approximately constantover time,with those individuals atdual risk showinghigher
comorbidity scores compared with those without.
CONCLUSIONS
Thesefindings, showing greater risk of SHEs after CV events aswell as greater risk of
CV events after SHEs, validate a bidirectional relationship between CV events and
SHEs in patients with high comorbidity scores.
In the post-2008 era of cardiovascular outcome trials (CVOTs) mandated by the U.S.
Food and Drug Administration (FDA) for any new glucose-lowering drug, severe
hypoglycemic events (SHEs) requiring third-party assistance have remained a major
challenge complicating diabetes therapy (1). Post hoc analyses of several CVOTs have
1Munich Diabetes Research Group e.V. at Helm-
holtz Centre, Neuherberg, Germany
2Duke Clinical Research Institute, Duke University 
School of Medicine, Durham, NC
3Diabetes Trials Unit, Oxford Centre for Diabetes, 
Endocrinology and Metabolism, University of 
Oxford, Oxford, U.K.
4University of North Carolina School of Medicine, 
Chapel Hill, NC
5AstraZeneca Research and Development, Gai-
thersburg, MD
6ANMCO Research Center, Florence, Italy
Corresponding author: Eberhard Standl, eberhard. 
standl@lrz.uni-muenchen.de
Received 29 May 2019 and accepted 21 October 
2019
Clinical trial reg. no. NCT01144338, clinicaltrials 
.gov.
This article contains Supplementary Data online at 
https://care.diabetesjournals.org/lookup/suppl/
doi:10.2337/dc19-1079/-/DC1.
M.A.B. is currently affiliated with Eli Lilly and Co., 
Indianapolis, IN.
Eberhard Standl,1 Susanna R. Stevens,2
Yuliya Lokhnygina,2 M. Angelyn Bethel,3
John B. Buse,4 Stephanie M. Gustavson,5
Aldo P. Maggioni,6 Robert J. Mentz,2
Adrian F. Hernandez,2 andRury R. Holman,3
for the EXSCEL Study Group
found that SHEs are associated with an
increased risk of subsequent cardiovas-
cular (CV) and all-cause mortality (ACM)
events (2–9). These findings, and the lack
of compelling evidence for CV benefit
from intensive glycemic control in pa-
tients with established CV disease, have
prompted many diabetes management
guidelines to suggest relaxing individual
glycated hemoglobin (HbA1c) targets in
such patients in the anticipation that this
will reduce SHEsandassociatedmortality
events (10,11). Higher HbA1c targets,
however, may increase the risk of mi-
crovascular complications in the longer
term,andhavenotbeenshownto reduce
the risk of SHEs (4,12,13). Indeed, in the
Action to Control Cardiovascular Risk in
Diabetes (ACCORD) trial, patients with
higher HbA1c values had a greater risk of
SHEs, irrespectiveof the treatment group
(4), and the risk of ACM was greatest in
the participants with the highest average
HbA1c values, especially in the intensive
treatment arm (14). On the other hand,
SHEs did not account for the difference in
mortality between the two study arms
(4), and transferring the intensive treat-
ment group to less strict HbA1c targets
between 7.0% and 7.9% left the in-
creased risk of ACM and CV death un-
changed (15). Accordingly, it is unclear to
what extent SHEs may play a causative
role in ACMandCVevents,with common
confounders being a realistic alternative
explanation. Of note, a strong reverse
association, in which nonfatal CV events
were associated with a subsequent in-
creased risk of SHEs, was demonstrated
in a post hoc analysis of TECOS (Trial Eval-
uating Cardiovascular Outcomes With
Sitagliptin) (8).
We sought to confirm in this post hoc
analysis of data from EXSCEL (Exenatide
Study of Cardiovascular Event Lowering)
(16) that there is a bidirectional relation-
ship between an increased risk for CV
events after SHEs and an increased risk
for SHEs after nonfatal CV events, par-
ticularly in patients at dual risk with
features of “frailty” as evidenced by a
high summary comorbidity score.
RESEARCH DESIGN AND METHODS
Study Design and Participants
EXSCEL was a double-blind, placebo-
controlled, randomized, event-driven tri-
al conducted at 687 sites in 35 countries.
It was designed to assess the CV safety of
extended-release exenatide given once
weekly versus placebo when added to
usual care in patients with type 2 di-
abetes; the results have been reported in
detail (16). The trial was designed such
that;70% of enrolled patients had pre-
vious CV events and 30% did not. EXSCEL
was run jointly by the Duke Clinical Re-
search Institute (DCRI) and theUniversity
of Oxford Diabetes Trials Unit in an
academically independent collaboration
with the sponsor, Amylin Pharmaceuti-
cals (a wholly owned subsidiary of
AstraZeneca). The protocol was approved
by the ethics committee at each partici-
pating site, and the statistical analyses
were performed by the DCRI, indepen-
dentof the sponsor. All patients provided
written informed consent. Eligible pa-
tients were adults with type 2 diabetes
and with an HbA1c level of 6.5–10.0%
(48–96mmol/mol) inclusive. Previous CV
events were defined as a history ofmajor
clinical manifestation of coronary artery
disease, ischemic cerebrovascular dis-
ease, or atherosclerotic peripheral arte-
rial disease. In addition, the summary
comorbidity score at baseline was as-
sessed using the Charlson Comorbidity
Index (17,18). History of two or more
episodes of severe hypoglycemia (de-
finedashypoglycemia forwhich apatient
received third-party assistance) during
the preceding 12 months was a principle
exclusion criterion.
Randomization and Study Medication
EXSCEL participants were randomly
assigned in a 1:1 ratio to receive sub-
cutaneous injections of once-weekly
exenatide (EQW) at a dose of 2 mg or
matching placebo. Participants were
required to discontinue study medica-
tion if they had two or more SHEs be-
tween trial visits (despite adjustment
of other glucose-lowering agents), had
irreversible kidney dysfunction (con-
firmed by two consecutive estimated
glomerular filtration rate [eGFR] values
,30 mL/min/1.73 m2), or received renal
replacement therapy. For minimization
of potential confounding effects of differ-
ential glycemic levels on trial outcomes,
the use of open-label glucose-lowering
agents (including dipeptidyl peptidase 4
inhibitors but not including glucagon-like
peptide 1 receptor agonists) was encour-
aged to promote glycemic equipoise be-
tween the two trial groups and to help
patients reach clinically appropriate
HbA1c targets.
SHEs
At screening/enrollment, 1 week, 2
months, 6 months, and 12 months, and
then at semiannual visits, the symptoms
and appropriate management of hypo-
glycemiawere reviewed proactively with
participants. All SHEs were recorded
systematically as prespecified events
of clinical interest. SHEs were defined
per protocol as episodes in which a
participant was sufficiently disoriented
or incapacitated as to require help from
either another individual or frommedical
personnel, i.e., third-party assistance,
irrespective of whether this assistance
was actually provided. It did not suffice,
for example, if a family member or other
bystander brought the patient a snack or
drink to help raise his or her blood
glucose if it was not clear that the patient
could not have done this unaided. This
category included all patients who had at
least one SHE that was reported during
the overall period, which was defined as
the period from the date of randomiza-
tion through the lastdate that thepatient
was known to be alive.
Clinical Outcomes
Major adverse CV events (MACE) consti-
tuted the EXSCEL primary composite
outcome, defined as the first occurrence
of CV death, nonfatal myocardial infarc-
tion (MI), or nonfatal stroke, which was
evaluated in a time-to-event analysis.
Secondary outcomes, also evaluated in
time-to-event analyses, included ACM,
CV death, the first occurrence of nonfatal
or fatal MI, nonfatal or fatal stroke,
hospitalization for acute coronary syn-
drome (hACS), and hospitalization for
heart failure (hHF). An independent clin-
ical events classification committee
whose members were unaware of the
trial-group assignments adjudicated all
the components of the primary and
secondary outcomes, ventricular arrhyth-
mias that led to intervention, neoplasms,
and pancreatitis. Prespecified events of
clinical interest for which information
was collected systematically at every
follow-up visit, regardless of serious-
ness, were pancreatitis, neoplasm, SHEs,
and expected CV or diabetes-related
complications.
Statistical Analysis
Categorical variables are presented as n
(%), and continuous variables are pre-
sented asmedian (25th, 75th percentile).
Risk of first SHE as a function of time is
shown with Kaplan-Meier plots, with
study treatment differences tested using
Cox proportional hazards regression
models stratified by prior CV disease.
Treatment effects for EQW versus pla-
cebo are presented as hazard ratios (HRs)
and 95% CIs, with numbers of events and
eventsper 100patient-yearsof follow-up
reported. Using the same approach, we
further subdivided both treatment arms,
considering patients on “insulinotropic”
therapies (insulin, sulfonylureas, or nonsul-
fonylurea insulin secretagogues) compared
with those without such drugs, and the
randomized treatment–by–insulinotropic
therapy interaction was evaluated.
For investigation of the association
between SHEs and CV events, Cox pro-
portional hazards regression models
were fittedwith SHEs as time-dependent
variables and subsequent MACE, as well
as fatal/nonfatalMI or stroke, hACS, hHF,
and ACM, as outcomes. For investigation
of the reverse association, Cox models
were fitted with nonfatal CV events as
time-dependent variables and subse-
quent SHEs as outcomes. For both anal-
yses, unadjusted as well as partially and
fullyadjustedmodelswereused.Partially
adjusted models included randomized
treatment and clinical factors of age,
sex, ethnicity, weight, and current smok-
ing, while models fully adjusted for in-
dependent predictors of MACE and ACM
in EXSCEL (19) included age, sex, ethnic-
ity, HbA1c, New York Heart Association
class, current smoking, randomized treat-
ment, MI, CV disease, stroke, $50% ste-
nosis in carotid artery, atrial fibrillation
or flutter, systolic blood pressure, dia-
stolic blood pressure, heart rate, height,
BMI, eGFR, diabetes duration, insulin
therapy at baseline, time-dependent in-
sulin use during the trial, chronic res-
piratory disease, amputation, diabetic
neuropathy, and foot ulcers as covari-
ates.Models for SHE outcomeswere also
adjusted for baseline b-blockers and sul-
fonylureas. For the continuous variables,
we checked whether nonlinear terms
(piecewise splines) needed to be in-
cluded in the models. Where piecewise
splines for continuous variables were
necessary, a cut point was selected that
would work reasonably well for all end
points. The proportional hazards as-
sumption was checked for the full ad-
justmentmodelwithnomajor violations
being identified.
Models for CV outcomes used only the
first SHE per patient and assumed that
therewereno time-dependent confound-
ers associated with both SHEs and clinical
outcomes. Events per 100 patient-years
of follow-up are presented separately for
the time fromfirst SHE to clinical outcome
and for time to clinical outcome or censor
without an SHE. Results are displayed as
forest plots. Analyses of the association
between nonfatal CV outcomes and sub-
sequent SHEs were conducted and pre-
sented similarly.
To investigate the time dependence of
the riskofCVevents after SHEs, nonlinear
restricted cubic spline functions of time
since SHE were included in fully adjusted
proportional hazards regression models.
These functions were exponentiated to
get HRs associatedwith SHE as a function
of time since SHE and plotted for the
range of follow-up times postevent. Risk
of SHEas a functionof timesincenonfatal
CV events was investigated using the
same approach. P values for whether
the HRs were constant over time are
provided. Data were analyzed using SAS
software, version 9.4 (SAS Institute, Cary,
NC), with P values ,0.05 considered
statistically significant.
RESULTS
The EXSCEL intention-to-treat popula-
tion consisted of 14,752 patients (of
whom 10,782 [73.1%] had previous CV
disease) with a median follow-up of 3.2
years (interquartile range 2.224.4). A
total of 14,187 participants (96.2%) com-
pleted the trial, and vital status was
obtained for 98.8% of the participants.
Themedian durationof exposure to study
medicationwas 2.4 years (1.423.8) in the
EQWgroupand2.3years (1.223.6) in the
placebo group. No patients were ex-
cluded from the trial because of a history
of two SHEs.
SHEs were relatively uncommon and
not associated with EQW therapy (N 5
247 [3.4%], 1.0/100 patient-years, vs.
N 5 219 [3.0%], 0.9/100 patient-years
for placebo; HR 1.13 [95% CI 0.9421.36],
P 5 0.179) (Fig. 1A). Subgroups with or
without baseline therapy that included
insulin, sulfonylurea, or nonsulfonylurea
secretagogues also showed no differ-
ence between the two treatment arms
(HR 1.12 [95% CI 0.9321.36]) for the
subgroup with insulin, sulfonylurea, or
nonsulfonylurea secretagogues and HR
1.24 [95% CI 0.6122.51] for the group
without; P 5 0.80 for interaction) (Fig.
1B). Incidence rates for SHEswere higher
in the 1st year than thereafter in both
treatmentgroupsandwerehighest in the
subgroup with insulin, sulfonylurea, or
nonsulfonylurea secretagogue therapy
at baseline compared with those on
other therapies at baseline (HR 4.17
[95% CI 2.90–6.02]). Recurrent SHEs
were balanced between treatment arms,
seen in 71 placebo participants and 62
EQW participants. There was a total of
450 events (1.8/100 patient-years) in the
placebo group and 404 in the EQW group
(1.6/100 patient-years). Two participants
in the placebo group and four in the EQW
group discontinued study drug because of
SHEs.
Baseline characteristics for those with
and without an SHE during the trial are
listed in Table 1. Participantswith an SHE,
compared with those without, had lon-
ger diabetes duration and lower eGFR,
more frequently had prior CV or heart
failure events, and were more often
nonwhite or insulin treated and with a
higher daily dose per kilogram of body
weight. Furthermore, participants with
SHEs were more often treated with di-
uretics, statins,b-blockers, and antithrom-
botic agents. Of the 466participantswith
SHEs, 15 (3.2%) died of non-CV causes
and 116 (24.9%) had a CV event (i.e., MI,
stroke, hHF, hACS, or CV death). Of these
116 participants, 66 had these events
after an SHE during the trial (with four
participants having an SHE on the same
day) and 50 participants had an SHE
after a nonfatal CV or hHF event during
the trial. The baseline characteristics of
the latter two groups are also listed in
Table 1, compared with the 14,636 EX-
SCEL participants who did not have an
SHE or a CV event during the trial. Those
two groups with, compared with those
without, concomitant SHEs and CV
events during the trial showed rather
similar characteristics andwere;4 years
older, had a 4-year longer duration of
diabetes, and were almost twice as likely
to be insulin treated. In addition, their
daily insulin dose at baseline was higher
compared with those without the dual
risk (0.82 vs. 0.62 units/kg body wt) (see
also Supplementary Table 1). They com-
prised fewer women; were more often
black; tended to have a higher BMI and
HbA1c; had twice the proportion with
chronic kidney disease stage 3 (eGFR 30–
59 mL/min/1.73 m2); more frequently
reported a history of CV disease, heart
failure, and prior CV events; showed a
markedly higher Charlson Comorbidity
Index; and were more often treated
with acetylsalicylic acid, thienopyridines,
statins, diuretics, and b-blockers. These
trends were most pronounced in the
group with an SHE before a CV event,
with 97% having experienced a prior CV
event, 41% with a prior heart failure
history, and 46% with chronic kidney
disease stage 3. Those patients also
had the highest daily insulin dose (0.87
units/kgbodywt). Of the fourparticipants
with an SHE and a CV event occurring on
the same day, three were taking insulin at
baseline and the other had commenced
insulin therapyprior to theevents. Twodied
within 2 days from CV death and non-CV
death, while the other two remained free
from further events.
In analyses adjusted for selected clin-
ical factors, SHEs were associated with a
subsequent increased risk of the primary
MACE end point (HR 1.43 [95% CI 1.08–
1.91], P5 0.013), ACM (HR 2.06 [95% CI
1.57–2.71],P,0.001), CVdeath (HR1.84
[95% CI 1.28–2.62], P 5 0.001), MI (HR
1.68 [95%CI1.18–2.39],P50.004), hACS
(HR 1.66 [95% CI 1.19–2.30], P5 0.003),
and hHF (HR 2.88 [95%CI 1.92–4.33], P,
0.001) (Fig. 2A). Conversely, nonfatal MI
or stroke (HR 2.50 [95% CI 1.75–3.56],
P, 0.001), nonfatal MI (HR 2.52 [95% CI
1.70–3.74], P , 0.001), nonfatal stroke
(HR 2.56 [95% CI 1.40–4.70], P5 0.002),
hACS (HR 2.42 [95% CI 1.68–3.48], P ,
0.001), and hHF (HR 4.40 [95% CI 2.70–
7.15], P , 0.001) were associated with a
subsequent increasedriskofSHEs (Fig.2B).
In fully adjusted models, statistically
significant associations of SHEs with sub-
sequent eventswere limited to CVdeath,
ACM, and hHF events (Fig. 2C), while
all associations between nonfatal CV
events and subsequent increased risk
of SHEs remained statistically significant
(Fig. 2D).
After adjustment for the full list of
covariates, the elevated hazards of
combined CV events (MACE/hACS/hHF)
following SHEs and of SHEs following
combined nonfatal CV events (nonfatal
MACE/hACS/hHF) were approximately
constant over time (Fig. 3A and B). The
hazard for ACM following hypoglycemia,
however, changed over time (P, 0.001),
beinggreatest(approximatelyfivefold)soon
after an SHE, decreasing over the first 2
years to about normal levels and increasing
again after;3yearspost-SHE, although the
numbers at risk beyond 3 years decreased
and 95%CIs widened substantially (Fig. 3C).
A similar patterndalbeit only of borderline
significancedwas seen with single time-
dependent hazard plots for MACE and CV
death after an SHE (P 5 0.031 for MACE
and 0.056 for CV death) (Supplementary
Fig. 1) but not for hACS or hHF.
CONCLUSIONS
The primary objective of this workdto
validate the hypothesis of a bidirec-
tional relationship for an increased risk
of CV events after SHEs as well as an
increased risk of SHEs after CV events in
patients with type 2 diabetesdwas met.
We found consistent evidence again
confirming a greater risk of CV death,
ACM, or hHF after SHEs, with also a
substantially higher risk of SHEs after a
nonfatal CV event such as nonfatal MI,
stroke, hACS, or hHF.Moreover, we have
demonstrated that the elevated hazards
of combined CV events following SHEs
and SHEs following combined nonfatal
CV events were approximately constant
over time, while the specific hazard for
all-causedeathdandto someextentalso
Figure 1—Kaplan-Meier plots of time tofirst SHE for participants assigned to exenatide or placebo.
A: In the intention-to-treat population. B: Split by those with or without therapy with insulin,
sulfonylurea (SU), or nonsulfonylurea secretagogues (NSS) at baseline.
Table 1—Baseline patient characteristics according to CV and SHEs occurring during the study




CV event before SHE
during trial (N 5 50)
SHE before CV event
during trial (N 5 66)*
DidnothaveSHEandCVevent
during trial (N 5 14,636)
Age at randomization
(years) 62 (56, 68) 63 (57, 70) 67 (59, 71) 65 (61, 70) 62 (56, 68)
Female sex 5,422 (38.0) 181 (38.8) 15 (30.0) 16 (24.2) 5,572 (38.1)
Race
White 10,865 (76.1) 310 (66.5) 33 (66.0) 50 (75.8) 11,092 (75.8)
Black 832 (5.8) 46 (9.9) 6 (12.0) 5 (7.6) 867 (5.9)
Asian 1,402 (9.8) 50 (10.7) 4 (8.0) 6 (9.1) 1,442 (9.9)
Other 1,182 (8.3) 60 (12.9) 7 (14.0) 5 (7.6) 1,230 (8.4)
Duration of type 2
diabetes (years) 12 (7, 17) 14 (9, 22) 16 (11, 22) 17 (10, 24) 12 (7, 18)
History of CV disease
Coronary artery disease 7,505 (52.5) 289 (62.0) 36 (72.0) 55 (83.3) 7,703 (52.6)
Cerebrovascular
disease 2,419 (16.9) 90 (19.3) 11 (22.0) 23 (34.8) 2,475 (16.9)
Peripheral artery
disease 2,712 (19.0) 88 (18.9) 13 (26.0) 12 (18.2) 2,775 (19.0)
CV event
Prior CV event 10,421 (72.9) 361 (77.5) 43 (86.0) 64 (97.0) 10,675 (72.9)
CV disease without
prior event 143 (1.0) 6 (1.3) 0 (0) 0 (0) 149 (1.0)
Neither prior CV event
nor disease 3,722 (26.1) 99 (21.2) 7 (14.0) 2 (3.0) 3,812 (26.0)
Heart failure 2,291 (16.0) 98 (21.0) 16 (32.0) 27 (40.9) 2,346 (16.0)
Charlson Comorbidity
Index 5 (4, 7) 6 (5, 8) 7 (5, 9) 8 (6, 9) 5 (4, 7)
Systolic blood pressure
(mmHg) 135 (124, 145) 135 (125, 148) 136 (127, 145) 131 (120, 145) 135 (124, 145)
Diastolic blood pressure
(mmHg) 80 (70, 85) 78 (70, 82) 77 (68, 82) 77 (65, 81) 80 (70, 85)
Heart rate (bpm) 72 (66, 80) 72 (65, 80) 74 (64, 80) 73 (66, 84) 72 (66, 80)
BMI (kg/m2) 31.8 (28.3, 36.2) 31.6 (27.9, 36.5) 32.7 (29.7, 36.9) 33.3 (28.6, 37.5) 31.8 (28.2, 36.2)
HbA1c (%) 8.0 (7.3, 8.9) 8.1 (7.5, 8.9) 8.6 (7.7, 9.4) 8.0 (7.3, 9.1) 8.0 (7.3, 8.9)
Total cholesterol (mg/dL) 166 (138, 201) 163 (137, 197) 164 (138, 200) 146 (123, 176) 166 (138, 201)
LDL (mg/dL) 88 (66, 116) 87 (65, 119) 80 (60, 104) 77 (62, 104) 88 (66, 116)
HDL (mg/dL) 42 (35, 50) 42 (35, 49) 42 (34, 49) 38 (32, 44) 42 (35, 50)
Triglycerides (mg/dL) 159 (114, 228) 163 (106, 230) 170 (106, 255) 162 (104, 222) 159 (114, 228)
eGFR (mL/min/1.73 m2) 77 (61, 92) 70 (55, 86) 64 (54, 87) 61 (45, 80) 76 (61, 92)
$90 4,172 (29.3) 96 (20.6) 11 (22.0) 9 (13.6) 4,248 (29.1)
60–89 7,027 (49.3) 219 (47.1) 19 (38.0) 27 (40.9) 7,200 (49.4)
30–59 3,027 (21.3) 150 (32.3) 20 (40.0) 30 (45.5) 3,127 (21.4)
,30 14 (0.1) 0 (0) 0 (0) 0 (0) 14 (0.1)
CV medications
Aspirin 9,055 (63.4) 325 (69.7) 38 (76.0) 58 (87.9) 9,284 (63.4)
Thienopyridines 2,426 (17.0) 98 (21.0) 16 (32.0) 24 (36.4) 2,484 (17.0)
Any antiplatelets 10,472 (73.4) 363 (77.9) 45 (90.0) 60 (90.9) 10,730 (73.4)
ACEI or ARB 11,024 (77.2) 374 (80.3) 38 (76.0) 52 (78.8) 11,308 (77.3)
b-Blockers 7,933 (55.5) 278 (59.7) 36 (72.0) 49 (74.2) 8,126 (55.5)
Calcium channel
blockers 4,550 (31.8) 160 (34.3) 14 (28.0) 28 (42.4) 4,668 (31.9)
Any antihypertensive 12,894 (90.3) 429 (92.1) 49 (98.0) 65 (98.5) 13,209 (90.3)
Statin 10,479 (73.4) 366 (78.5) 41 (82.0) 59 (89.4) 10,745 (73.4)
Any lipid-lowering
medication 10,992 (76.9) 378 (81.1) 42 (84.0) 59 (89.4) 11,269 (77.0)
Diuretics 6,208 (43.5) 235 (50.4) 34 (68.0) 46 (69.7) 6,363 (43.5)
Continued on p. 648
for CV death and MACEdfollowing an
SHE changed in a time-dependent way,
with highest excess risk closest to the
time the SHE occurred. Notably, those
individuals at dual risk of SHEs and CV
eventsdregardless of the time sequenced
were characterized by much higher Charlson
Comorbidity Index scores compared
with those without.
TheseEXSCEL-derived results aremore
robust than those for TECOS (8), as the
number of patients with concomitant
SHEs and a CV event was ;70% larger.
As with the TECOS results, but unlike
most other reports regarding SHEs and
CV events, these EXSCEL results were
adjusted for all major predictors of CV
outcomes in the trial including prior CV
disease, heart failure, eGFR, duration of
diabetes, insulin therapy at baseline, and
new insulin use during the trial. Also, the
plots of time-dependent HRs were
done with full adjustment. Neverthe-
less, the finding of a two- to threefold
increased risk for SHEs after nonfatal CV
events persisted and remained approx-
imately constant over time, while the
Table 1—Continued




CV event before SHE
during trial (N 5 50)
SHE before CV event
during trial (N 5 66)*
DidnothaveSHEandCVevent
during trial (N 5 14,636)
Diabetes medications
Biguanide 10,982 (76.9) 313 (67.2) 29 (58.0) 39 (59.1) 11,227 (76.7)
Sulfonylurea 5,253 (36.8) 148 (31.8) 11 (22.0) 14 (21.2) 5,376 (36.7)
Insulin 6,509 (45.6) 327 (70.2) 40 (80.0) 52 (78.8) 6,744 (46.1)
Dose (units/kg
body wt) 0.62 (0.39, 0.89) 0.73 (0.45,1.07) 0.72 (0.43, 1.12) 0.87 (0.52, 1.19) 0.62 (0.39, 0.90)
DPP-4i 2,148 (15.0) 55 (11.8) 1 (2.0) 6 (9.1) 2,196 (15.0)
TZD 565 (4.0) 14 (3.0) 0 (0) 4 (6.1) 575 (3.9)
Other 610 (4.3) 14 (3.0) 0 (0) 3 (4.5) 621 (4.2)
Insulin/sulfonylurea/
NSS 11,005 (77.0) 435 (93.3) 48 (96.0) 63 (95.5) 11,329 (77.4)
Data are n (%) or median (25th, 75th percentile). ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; DPP-4i, dipeptidyl peptidase 4 inhibitor; NSS,
nonsulfonylurea secretagogues; TZD, thiazolidinedione. *Four patients with CV event and SHE on the same day are included with the SHE before CV
event group.
Figure2—Forestplots showing theassociationofSHEsandsubsequent riskofCVoutcomes (AandC) andnonfatalCVeventsandsubsequent riskofSHEs
(B andD). Models forA and Bwere adjusted for clinical factors (randomized treatment, age, sex, ethnicity, weight, and smoking), whereasmodels for C
andDwere fully adjusted for age, sex, ethnicity, HbA1c level, New York Heart Association class, current smoking, history ofMI, coronary artery disease,
stroke, stenosisof carotidartery, atrialfibrillation, chronicobstructivepulmonarydisease, amputation,diabeticneuropathy, footulcers,baseline insulin
therapy, systolic blood pressure, diastolic blood pressure, heart rate, height, BMI, eGFR, diabetes duration, randomized treatment, and insulin use as
a time-dependent variable. Models for panel D were additionally adjusted for baseline b-blockers and baseline sulfonylurea. ACS, acute coronary
syndrome; HF, heart failure.
increased risk of 60% for CV death and
;80% for all-cause death after an SHE is
quite comparable with other publica-
tions including the finding of these haz-
ards beingmost frequent close to an SHE
(3,4,6,7,9,20,21). The significant associ-
ation of hHF in both directions with SHEs
is another interesting new observation.
Importantly, assigned treatment with
EQW was not associated with different
rates of SHEs between randomized study
groups.
Although associations found in epide-
miologic patient cohorts are not able to
prove a causal relationship between the
A B
C
Figure 3—Time-dependent HR plots with 95% CIs and numbers at risk for combined CV events (MACE/hACS/hHF). A: Occurring after an SHE. B: For an
SHE after a nonfatal CV event (MACE/hACS/hHF). C: For all-cause death after an SHE. P values for the test of constant HR over time are provided.
parameters studied, the bidirectional re-
lationship between SHEs and CV out-
comes, together with a higher Charlson
Comorbidity Index of;8 in those at dual
risk of SHEs and CV events, suggests that
there may be a common type 2 diabetes
phenotype of patients with multiple co-
morbidities and likely featuresof “frailty”
who are susceptible to both of these
events. Thus, SHEs in many, if not most,
instancesdrather than being causative
of CV death, hHF, or all-cause death
eventsdmay simply be indicative of mul-
timorbid or “frail” patients who are at
higher risk of both outcomes likely due
to a large accumulation of coexisting risk
factors. That there were four patients in
EXSCEL with same-day events does not
seem to exclude or confirm a causal role
of SHEs for CV outcomes.
These observations of EXSCEL data
also shed light on the emerging charac-
teristics of this patient phenotype at dual
risk for SHEs and CV events. Compared
with thosewithout this dual risk, patients
are considerably older, have a 4-year-
longer duration of diabetes, and are
more likely (80% vs. 37%) to be insulin
treated (and with a higher dose) at study
entry, with a further increase of insulin
users within the trial. Almost all had a
prior CV event either at study baseline
preceding the first SHE in the study or
occurringbefore anSHEduring the study.
Some 43% had chronic kidney disease
stage 3 at study entry, and more than
one-third had a history of heart failure,
with all these factors adding up to in-
creased SHE risk and risk of fatal and
nonfatal CV events, hHF events, and
ACM. The high comorbidity score for
these patients, as evidenced by a high
Charlson Comorbidity Index, seems also
to be reflected by their much greater use
of CV medications, especially of antipla-
telet therapies,b-blockers, diuretics, and
statins. Of note, baseline HbA1c concen-
trations of these patients did not differ
from those without dual risk or even
showed a trend to higher levels.
These characteristics of an emerging
“vulnerable” phenotype at dual risk for
SHEs and CV events are mirrored by the
recently studied populations at dual SHE
and CV event risk in the Liraglutide Effect
and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER)
trial and the Trial Comparing Cardiovascu-
lar Safetyof InsulinDegludecVersus Insulin
Glargine in PatientsWith Type2Diabetes
at High Risk of Cardiovascular Events
(DEVOTE), as well as in TECOS and the
Veterans Affairs Diabetes Trial (VADT)
(7–9,20). Epidemiological observations
from the Hong Kong Diabetes Registry
alsoseemtosupport thenovel conceptof
theexistenceof suchaparticularly frail or
vulnerable patient phenotype (22,23).
Remarkably, a recent publication from
the Atherosclerosis Risk in Communities
(ARIC) cohort study group looking at
severe hypoglycemia, mild cognitive im-
pairment, dementia, and brain volumes
in older adults with type 2 diabetes
described a very similar at-risk patient
phenotype with longer diabetes dura-
tion,olderage, andmorecommon insulin
use (24). Finally, the characteristics of
a vulnerable patient phenotype at dual
risk for SHEs and CV events seemingly
resemble a recently suggested “renal”
subphenotype cluster of adult-onset
diabetes (25).
Mechanistically, SHEs have been as-
sociatedwith hypokalemia, prolongation
of theQTc interval on electrocardiogram,
and neuro-sympathetic overdrive with
marked increase of blood pressure,
tachycardia, and various kinds of ar-
rhythmias (18,26–29). Moreover, SHEs
activate prothrombotic and proinflam-
matory pathways, factors that all add
up to a theoretical increased CV risk
(21,30–33). Our results are compatible
with the notion that these pathophysio-
logical mechanismsmay have been critical
tosomeindividualpatientsdperhapseven
beyond the CV contextdespecially when
considering the segment section closest
to the SHE of the time relationship with
all-cause death and, to a lesser extent,
with CV death. Alternatively, the close
time association between an SHE and
non-CV death in some patients may
just indicate excessive comorbidities in
those. In this context, the example of the
four patients with same-day dual SHEs
and CV events shows the complexity and
diversity of such a potential interaction.
Furthermore, in others, an SHE had oc-
curred long before a CV event, render-
ing a causative role of SHEs for CV
events in these patients rather unlikely.
The gradual recurrenceof an increased risk
for ACM beyond 3 years after an SHEd
although with numbers at risk declining,
which limits any firm conclusionsdwas
an unexpected finding potentially alluding
to a persisting high comorbidity score that
should be further explored.
In terms of SHEs occurring after a CV
event including hHF, brain natriuretic
peptides may play an important role,
as theydamong many other effectsd
activate insulin-sensitizing mechanisms
at the level of skeletalmuscle and adipose
tissue and increase circulating concentra-
tions of the insulin-sensitizing hormone
adiponectin (34,35).Anaugmentingeffect
of atrial natriuretic peptide on insulin-
induced hypoglycemia has long been
known (36). The strongest associations
seen in our analyses were between hHF
and SHEs in both settings of SHEs, before
and after a CV event. History of known
heart failure at baseline was rather fre-
quent at baseline in both groups with
dual SHE and CV events (32% and 41%,
respectively). Potentially, a similarly high
proportion of patients with heart failure
go unrecognized in most CVOTs focusing
on patients with established CV disease
unless natriuretic peptide levels aremea-
sured (37). Heart failure patientswith the
highest levels of both natriuretic pepti-
des and adiponectin have been found to
have the highest mortality risk (38). In
this context, continued use of insulin in
those patients may be questioned.
Strengths of our study include the size
and length of follow-up with proactive
collection and independent, blinded ad-
judication of all relevant events in the
contextofaCVOT.Thenumberofpatients
with dual SHEs and CV events (n 5 116)
is to our knowledge the largest reported
from a CVOT thus far. Moreover, our
results appear to be particularly robust
because of adjustment for a rather com-
prehensive list of potential confounders.
Though an evaluation of an a priori hy-
pothesis, study weaknesses include the
post hoc nature of the analysis and the
lack of available biomarkers such asmeas-
urements of natriuretic peptides to fur-
ther substantiate potential pathogenic
links. Moreover, whether less severe hy-
poglycemic episodes also might have im-
pacted the results could not be evaluated,
as theywere not systematically evaluated
in the pragmatic EXSCEL trial. This seems,
however, rather unlikely in light of neutral
findings related to less severe hypoglyce-
mia in studies such as the Outcome Re-
duction With Initial Glargine Intervention
(ORIGIN) or LEADER trials (6,9). Neverthe-
less, residual confounding cannot be ex-
cluded. Finally, a formal assessment of
frailty was not included in the EXSCEL
study protocol.
In summary, we report a robust bi-
directional association in EXSCEL partic-
ipants confirming a greater risk of SHEs
after CV events as well as a greater risk of
CV or all-cause death events after SHEs.
These findings support our view of an
existing common at-risk polymorbid and
potentially frail type 2 diabetes patient
phenotype, susceptible to both SHEs and
CV events. These vulnerable patients
with high comorbidity scores after a first
CV event in conjunction with heart fail-
ure, advanced kidney disease, older age,
longer duration of diabetes, and ten-
dency to be on insulin and on higher
doses warrant special consideration, in-
cluding careful dosing of insulin therapy.
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